Fovea and Genzyme enter gene therapy collaboration

Fovea Pharmaceuticals has entered into a collaborative research agreement with Genzyme Corporation.

The alliance is based around Fovea's proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dystrophies.

The two companies will collaborate to develop gene related therapies using this technology together with Genzyme's gene delivery techniques.